A recent retrospective analysis showed high response rates of induction chemotherapy, followed by AlloBMT in MDS and MDS/MPN patients with NPM1 mutations [116], suggesting that molecular profile may be critical for the identification of MDS/AML-MRC patients that may benefit from induction therapy. This evidence concerns the gene NPM1 and acute myeloid leukemia.